Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis

Figure 5

ROC curves of the metabolites (biomarker signature) results on plasma samples from all patients with pancreatic cancer versus healthy volunteers (a), from patients with diabetes mellitus versus healthy volunteers (b), and from patients with pancreatic cancer versus patients with diabetes mellitus (c). Models were tested through 5 repeated 5-fold cross-validation. AUC, area under the curve; combination1, model with top 5 metabolites selected from one-way ANOVA test; combination2, model with top 5 metabolites selected from Tukey’s honest significance test between diabetes mellitus patients and healthy volunteers; combination3, model with top 5 metabolites selected from Tukey’s honest significance test between pancreatic cancer patients and healthy volunteers; combination4, model with top 5 metabolites selected from Tukey’s honest significance test between pancreatic cancer patients and diabetes mellitus patients; and combination5, model with all the metabolites involved in previous 4 models.

(a)

(b)

(c)